News

Title Content Date
Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines Immuno-oncology collaboration aims to develop up to five cancer vaccines that target neoantigens across multiple tumor types / CureVac to receive an upfront payment of $50 million and an eq 19.10.2017
Atriva reaches a development milestone and receives an additional tranche of running seed financing to develop its influenza therapeutic to clinical stage The next generation of Antiviral Therapies: Co-Led by Stichting Participatie Atriva and High-Tech Gründerfonds (HTGF), Atriva Therapeutics GmbH has received a second tranche of its running seed fin 04.10.2017
Immatics Initiates Personalized Adoptive Cellular Therapy in Patients with Relapsed And/Or Refractory Solid Cancers Using Its Pioneering Target Warehouse Immatics, a leading company in the field of cancer immunotherapy, today announced that it 21.08.2017
Publication in EMBO Molecular Medicine Demonstrates CureVac’s Proprietary mRNA Technology Enables Antibody Mediated Therapies Against Infectious Agents, Toxins and Tumors Data validate the strength of CureVac’s RNAntibody® technology to produce high and sustained levels of antibody production in a variety of disease indications 16.08.2017
CureVac Announces Publication in The Lancet of First-Ever Human Proof-of-Concept Study Investigating the Safety and Immunogenicity of a Prophylactic mRNA Vaccine CureVac AG, a fully-integrated biotechnology company pioneering mRNA-based drugs, today announced that the re 26.07.2017
CureVac to Receive Patent Claiming the Combination of mRNA Vaccines with Anti-PD-1 Antibodies CureVac AG, a fully-integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced it has been granted a Notice of Allowance from the European Patent Office (EPO) fo 24.07.2017
CureVac Expands GMP Production Capacities for RNA Products CureVac AG, a fully-integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced during a public open door event at its main locatio 28.06.2017
Medicxi launches first $300m late-stage life sciences fund Medicxi Growth 1 (MG1), backed by Novartis and Verily Medicxi announced on June 15th the close of Medicxi Growth 1 (MG1), a new $300 million fund that will focus on growth stage companies in European life science 25.06.2017
CeGaT Obtains CLIA Certification, Final Step Towards U.S. Market Entry After receiving CAP accreditation in 2016, CeGaT has been granted Clinical Laboratory Improvement Amendments (CLIA) certification by The Centers for Medicare &amp 21.06.2017
CureVac Extends Global Intellectual Property Estate for Prophylactic mRNA Vaccines CureVac AG a fully-integrated biotechnology company pioneering mRNA-based drugs, today announced it has been granted important patents claiming the use of mRNA- 14.06.2017

Pages